Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J., May 14, 2025 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical... Read more.
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J., May 14, 2025 /PRNewswire/ — Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), a specialty... Read more.
Trusted Media Brands Appoints Media Executive Stephen Colvin as CEO
Colvin to replace long-time CEO Bonnie Kintzer following retirement NEW YORK, May 14, 2025 /PRNewswire/ — Trusted Media Brands, the community-driven entertainment... Read more.
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
PALO ALTO, Calif., May 14, 2025 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the... Read more.
Caldera Launches New Subscription Package for the Visual Communications, Industrial Printing and Packaging Industry
DOWNERS GROVE, Ill., May 14, 2025 /PRNewswire/ — Caldera, part of Dover (NYSE: DOV), today announced the launch of GrandRIP, a new subscription raster image... Read more.
Perrone Robotics Announces Formation of Dedicated Transit Division to Support Growth and Enhanced Customer Focus
CHARLOTTESVILLE, Va., May 14, 2025 /PRNewswire/ — Perrone Robotics, Inc., a pioneer and leader in autonomous vehicle technology, today announced the establishment... Read more.
Canaan Inc. Provides April 2025 Bitcoin Production and Mining Operation Updates
SINGAPORE, May 14, 2025 /PRNewswire/ — Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), an innovator in crypto mining, today... Read more.
MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Marpai’s turnaround momentum is building TAMPA, Fla., May 14, 2025 /PRNewswire/ — Marpai, Inc. (“Marpai” or the “Company”) (OTCQX:... Read more.
Precigen Reports First Quarter 2025 Financial Results and Business Updates
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company’s BLA for PRGN-2012 for the treatment of adults with RRP is under... Read more.
Inhibrx Reports First Quarter 2025 Financial Results
SAN DIEGO, May 14, 2025 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial... Read more.